Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2330b in Hemodialysis Patients
NCT03305471Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DS-2330b in hyperphosphatemia (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum concentration at 48 hours, Time to maximum concentration at 48 hours and 3 more. Started Aug 2017; status: completed.
02
Drugs
DS-2330b
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03305471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305471.